Comment on 'Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study'

被引：3
|
作者：
Dankner, Matthew [1 ,2 ]
Rose, April A. N. [3 ]
机构：
[1] McGill Univ, Goodman Canc Res Ctr, Montreal, PQ, Canada
[2] McGill Univ, Dept Med, Montreal, PQ, Canada
[3] Univ Toronto, Dept Med, Div Med Oncol, Toronto, ON, Canada
来源：
BRITISH JOURNAL OF CANCER | 2018年 / 118卷 / 09期
关键词：
RAS MUTATIONS;
D O I：
10.1038/s41416-018-0012-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1276 / 1277
页数：2
相关论文
共 50 条
  • [1] Comment on ‘Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study’
    Matthew Dankner
    April A. N. Rose
    British Journal of Cancer, 2018, 118 : 1276 - 1277
  • [2] Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study
    Shinozaki, Eiji
    Yoshino, Takayuki
    Yamazaki, Kentaro
    Muro, Kei
    Yamaguchi, Kensei
    Nishina, Tomohiro
    Yuki, Satoshi
    Shitara, Kohei
    Bando, Hideaki
    Mimaki, Sachiyo
    Nakai, Chikako
    Matsushima, Koutatsu
    Suzuki, Yutaka
    Akagi, Kiwamu
    Yamanaka, Takeharu
    Nomura, Shogo
    Fujii, Satoshi
    Esumi, Hiroyasu
    Sugiyama, Masaya
    Nishida, Nao
    Mizokami, Masashi
    Koh, Yasuhiro
    Abe, Yukiko
    Ohtsu, Atsushi
    Tsuchihara, Katsuya
    BRITISH JOURNAL OF CANCER, 2017, 117 (10) : 1450 - 1458
  • [3] Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study
    Eiji Shinozaki
    Takayuki Yoshino
    Kentaro Yamazaki
    Kei Muro
    Kensei Yamaguchi
    Tomohiro Nishina
    Satoshi Yuki
    Kohei Shitara
    Hideaki Bando
    Sachiyo Mimaki
    Chikako Nakai
    Koutatsu Matsushima
    Yutaka Suzuki
    Kiwamu Akagi
    Takeharu Yamanaka
    Shogo Nomura
    Satoshi Fujii
    Hiroyasu Esumi
    Masaya Sugiyama
    Nao Nishida
    Masashi Mizokami
    Yasuhiro Koh
    Yukiko Abe
    Atsushi Ohtsu
    Katsuya Tsuchihara
    British Journal of Cancer, 2017, 117 : 1450 - 1458
  • [4] Reply to 'Comment on 'Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study''
    Shinozaki, Eiji
    Yoshino, Takayuki
    Tsuchihara, Katsuya
    BRITISH JOURNAL OF CANCER, 2018, 118 (09) : 1278 - 1279
  • [5] Reply to `Comment on `Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study''
    Eiji Shinozaki
    Takayuki Yoshino
    Katsuya Tsuchihara
    British Journal of Cancer, 2018, 118 : 1278 - 1279
  • [6] Clinical impact of expanded BRAF mutational status on the outcome for metastatic colorectal cancer patients with anti-EGFR antibody: An analysis of the BREAC trial (Biomarker Research for Anti-EGFR Monoclonal Antibodies by Comprehensive Cancer Genomics).
    Yuki, Satoshi
    Yoshino, Takayuki
    Tsuchihara, Katsuya
    Shinozaki, Eiji
    Muro, Kei
    Nishina, Tomohiro
    Yamaguchi, Kensei
    Akagi, Kiwamu
    Yamazaki, Kentaro
    Yamanaka, Takeharu
    Nomura, Shogo
    Fujii, Satoshi
    Esumi, Hiroyasu
    Abe, Yukiko
    Ohtsu, Atsushi
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] Clinical impact of expanded BRAF mutational status on the outcome for metastatic colorectal cancer patients with anti-EGFR antibody: An analysis of the BREAC trial (Biomarker Research for Anti-EGFR Monoclonal Antibodies by Comprehensive Cancer Genomics).
    Yamazaki, Kentaro
    Yoshino, Takayuki
    Tsuchihara, Katsuya
    Shinozaki, Eiji
    Muro, Kei
    Nishina, Tomohiro
    Yamaguchi, Kensei
    Akagi, Kiwamu
    Yuki, Satoshi
    Yamanaka, Takeharu
    Nomura, Shogo
    Fujii, Satoshi
    Esumi, Hiroyasu
    Abe, Yukiko
    Ohtsu, Atsushi
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [8] Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer
    Zacharenia Saridaki
    Vassilis Georgoulias
    John Souglakos
    World Journal of Gastroenterology, 2010, 16 (10) : 1177 - 1187
  • [9] Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer
    Saridaki, Zacharenia
    Georgoulias, Vassilis
    Souglakos, John
    WORLD JOURNAL OF GASTROENTEROLOGY, 2010, 16 (10) : 1177 - 1187
  • [10] BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis
    Mao, Chen
    Liao, Ru-Yan
    Qiu, Li-Xin
    Wang, Xi-Wen
    Ding, Hong
    Chen, Qing
    MOLECULAR BIOLOGY REPORTS, 2011, 38 (04) : 2219 - 2223
12345